Masimo is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors.

 
 
  • Capnography Solutions
  • Partnering with caregivers and patient monitoring companies to provide a complete portfolio of capnography and gas monitoring solutions
 
  • rainbow® Pulse CO-Oximetry
  • The Masimo rainbow SET™ platform has the unique ability to measure dyshemoglobins and total hemoglobin concentration.
 
 
  • CCHD Screening
  • Reliable, Accurate Screening for Critical Congenital Heart Disease (CCHD) with Masimo SET®

News & Media

 
  • December 12, 2018
  • Washington, DC
  • Masimo (NASDAQ: MASI) Founder and CEO, Joe Kiani, was honored last night at the 2018 IPO Education Foundation Awards Dinner with the first ever IP Champion Award. The Intellectual Property Owners Education Foundation, a non-profit organization devote […]
  • November 12, 2018
  • Neuchatel, Switzerland
  • Masimo (NASDAQ: MASI) announced today that a new consensus statement on postoperative anemia management was published in Anaesthesia by an international panel of clinicians specializing in patient blood management, which includes clear guidance on th […]
  • October 25, 2018
  • Irvine, California
  • Masimo (NASDAQ: MASI) announced today that RD SET™ sensors with Masimo Measure-through Motion and Low Perfusion™ SET® pulse oximetry have received FDA clearance with improved SpO2 accuracy specifications for all patients > 3 kg. RD SET single-patient […]
  • March 2, 2018
  • Masimo Personal Health
  • MightySat is for people who want to improve their health, wellness, or fitness by providing key measurements that are more accurate & not available on other health and wellness devices. […]
  • February 23, 2018
  • Patient Safety Movement
  • The Patient Safety Movement Foundation believes reaching ZERO preventable deaths in hospitals by 2020 (0X2020™) is not only the right goal, but an attainable one with the […]
  • May 1, 2017
  • 2016 Masimo Annual Report
  • 2016 Masimo Annual Report - Through Movement. The first phase of our 10-year plan was to invest in R&D and key functional areas, allowing the company to gain a worldwide […]

Next Generation SedLine is not licensed for sale in Canada.

Caution: Federal (USA) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, and precautions.